Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies.

Objective: Charcot-Marie-Tooth (CMT) disease is most commonly caused by duplication of a chromosomal segment surrounding Peripheral Myelin Protein 22, or PMP22 gene, which is classified as CMT1A. Several candidate therapies reduce Pmp22 mRNA levels in CMT1A rodent models, but development of biomarke...

Descripción completa

Detalles Bibliográficos
Publicado en:Annals of Neurology Vol. 85; no. 6; pp. 887 - 899
Autores principales: Moran, John J., Ramesh, Raghu, Svaren, John, Wu, Xingyao, Bacon, Chelsea, Bai, Yunhong, Gutmann, Laurie, Anderson, Daniel M., Shy, Michael E., Zuccarino, Riccardo, Pavelec, Derek
Formato: research Journal Article
Publicado: Wiley-Blackwell Jun2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=136420284&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 136420284
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        03645134
        1WM
      jtl: Annals of Neurology
      issn: 03645134
      maglogo: Y
    pubinfo:
      dt: Jun2019
      vid: 85
      iid: 6
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        136420284
        136420284
        NLM30945774
        136420284
        10.1002/ana.25480
        NLM30945774
        136420284
      ppf: 887
      ppct: 12
      formats:
      tig:
        atl: Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies.
      aug:
        au:
          Moran, John J.
          Ramesh, Raghu
          Svaren, John
          Wu, Xingyao
          Bacon, Chelsea
          Bai, Yunhong
          Gutmann, Laurie
          Anderson, Daniel M.
          Shy, Michael E.
          Zuccarino, Riccardo
          Pavelec, Derek
        affil: Waisman Center, University of Wisconsin‐Madison, Madison WI
      sug:
        subj:
          Peripheral Nerves Pathology
          Charcot-Marie-Tooth Disease Pathology
          Skin Pathology
          Nerve Tissue Proteins
          Charcot-Marie-Tooth Disease
          Human
          Mice
          Middle Age
          Adolescence
          Skin
          Peripheral Nerves Metabolism
          Charcot-Marie-Tooth Disease Metabolism
          Male
          Biopsy
          Adult
          Aged
          Animal Studies
          Young Adult
          Female
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Funding Source
          Middle Aged: 45-64 years
          Adolescent: 13-18 years
          Adult: 19-44 years
          Aged: 65+ years
          Male
          Female
      ab: Objective: Charcot-Marie-Tooth (CMT) disease is most commonly caused by duplication of a chromosomal segment surrounding Peripheral Myelin Protein 22, or PMP22 gene, which is classified as CMT1A. Several candidate therapies reduce Pmp22 mRNA levels in CMT1A rodent models, but development of biomarkers for clinical trials in CMT1A is a challenge given its slow progression and difficulty in obtaining nerve samples. Quantitative PCR measurements of PMP22 mRNA in dermal nerves were performed using skin biopsies in human clinical trials for CMT1A, but this approach did not show increased PMP22 mRNA in CMT1A patients compared to controls. One complicating factor is the variable amounts of Schwann cells (SCs) in skin. The objective of the study was to develop a novel method for precise evaluation of PMP22 levels in skin biopsies that can discriminate CMT1A patients from controls.Methods: We have developed methods to normalize PMP22 transcript levels to SC-specific genes that are not altered by CMT1A status. Several CMT1A-associated genes were assembled into a custom Nanostring panel to enable precise transcript measurements that can be normalized to variable SC content.Results: The digital expression data from Nanostring analysis showed reproducible elevation of PMP22 levels in CMT1A versus control skin biopsies, particularly after normalization to SC-specific genes.Interpretation: This platform should be useful in clinical trials for CMT1A as a biomarker of target engagement that can be used to optimize dosing, and the same normalization framework is applicable to other types of CMT. ANN NEUROL 2019;85:887-898.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N